Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.43 |
| ▸ | CDK2 | P24941 | 3/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 7/20 | 0.42 |
| ▸ | CDK5R1 | Q15078 | 7/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | TUBB8B | A6NNZ2 | 1/20 | 0.36 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.36 |
| ▸ | TUBB | P07437 | 1/20 | 0.36 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.36 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.36 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.36 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23929715 | 1.00 | MEN1 (0.49) | MEN1KMT2ANPC1CCNA2CDK2 | |
| SCHEMBL23929754 | 1.00 | MEN1 (0.49) | MEN1KMT2ANPC1CCNA2CDK2 | |
| SCHEMBL23929851 | 1.00 | MEN1 (0.49) | MEN1KMT2ANPC1CCNA2CDK2 | |
| SCHEMBL23929688 | 1.00 | MEN1 (0.49) | MEN1KMT2ANPC1CCNA2CDK2 | |
| SCHEMBL23929751 | 1.00 | MEN1 (0.49) | MEN1KMT2ANPC1CCNA2CDK2 | |
| SCHEMBL25263226 | 0.92 | CDK5 (0.45) | MEN1KMT2ANPC1CCNA2CDK2 | |
| SCHEMBL30213187 | 0.92 | CDK5 (0.45) | MEN1KMT2ANPC1CCNA2CDK2 | |
| SCHEMBL26133679 | 0.92 | MEN1 (0.49) | MEN1KMT2ANPC1CCNA2CDK2 | |
| SCHEMBL23929472 | 0.91 | MEN1 (0.48) | MEN1KMT2ANPC1CCNA2CDK2 | |
| SCHEMBL30213167 | 0.91 | MEN1 (0.48) | MEN1KMT2ANPC1CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661869-A1 | COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS AND MODULATORS | Bayer Aktiengesellschaft (DE) | 2025-12-17 | — | — | EP | claimed |
| EP-4661870-A1 | COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-12-17 | — | — | EP | claimed |
| EP-4139286-B1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AG (DE) | 2025-02-26 | — | — | EP | claimed |
| WO-2024165470-A1 | COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-15 | — | — | WO | claimed |
| WO-2024165469-A1 | COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS AND MODULATORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-15 | — | — | WO | claimed |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | claimed |
| EP-4139286-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | Bayer Aktiengesellschaft (DE) | 2023-03-01 | — | — | EP | claimed |
| CN-115697980-A | Substituted aminothiazoles as DGKZETA inhibitors for immune activation | 拜耳公司 | 2023-02-03 | — | — | CN | claimed |
| WO-2021214019-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-28 | — | — | WO | claimed |
| EP-4661869-A1 | COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS AND MODULATORS | Bayer Aktiengesellschaft (DE) | 2025-12-17 | — | — | EP | disclosed |
| EP-4661906-A1 | COMBINATION OF CCR8 ANTIBODIES WITH DGK INHIBITORS IN THE TREATMENT OF CANCER | Bayer Aktiengesellschaft (DE) | 2025-12-17 | — | — | EP | disclosed |
| EP-4661870-A1 | COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024165470-A1 | COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-15 | — | — | WO | disclosed |
| WO-2024165468-A1 | COMBINATION OF CCR8 ANTIBODIES WITH DGK INHIBITORS IN THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-15 | — | — | WO | disclosed |
| WO-2024165469-A1 | COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS AND MODULATORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | MEN1 4344/4885KMT2A 1150/4885NPC1 3336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.